Acacia Pharma Group plc Share Price

ACPH

GB00BYWF9Y76

OTC Markets Traded

Latest news: Acacia Pharma Group plc

07-16	Acacia Pharma Group plc Announces the Termination of Debra Marie Hussain as Director, Effective July 13, 2026	CI
03/02/25	Acacia Pharma Group plc Auditor Raises 'Going Concern' Doubt	CI
03/02/25	Acacia Pharma Group plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI
21/07/24	Acacia Pharma Limited Appoints Debra Marie Hussain as Director	CI
09/06/22	Eagle Pharmaceuticals Completes Acacia Pharma Acquisition	MT
09/06/22	Acacia Pharma's Acquisition by Eagle Pharmaceuticals Closes; Shares Delist	MT
08/06/22	Acacia Pharma Group plc(ENXTBR:ACPH) dropped from Next Biotech Index	CI
07/06/22	Acacia Pharma's Acquisition by Eagle Pharmaceuticals Nears Completion	MT
05/06/22	Eagle Pharmaceuticals, Inc. completed the acquisition of Acacia Pharma Group plc from a group of shareholders.	CI
28/04/22	Acacia Pharma Group plc Auditor Raises 'Going Concern' Doubt	CI
28/04/22	Acacia Pharma Group plc Reports Earnings Results for the Full Year Ended December 31, 2021	CI
28/03/22	Health Care Up on Revival of Demand for Growth Sectors -- Health Care Roundup	DJ
28/03/22	FTSE 100 Closes Lower Despite Earlier Hopes on Russia, Ukraine Talks	DJ

More news

Analysts' recommendations: Acacia Pharma Group plc

01/10/21

Analyst recommendations: Acceleron Pharma, General Mills, Southwest Airlines, Home Depot, Wizz Air...

More recommendations

Press Releases: Acacia Pharma Group plc

09/06/22	Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care Footprint	AQ
09/06/22	Scheme of arrangement becoming effective	GL
09/06/22	Scheme of arrangement becoming effective	AQ
07/06/22	Court Sanction of the Scheme of Arrangement	GL
07/06/22	Court Sanction of the Scheme of Arrangement	AQ

More press releases

News in other languages: Acacia Pharma Group plc

07/06/22	Bel20 beperkt zijn verliezen bij het slot
07/06/22	Brussel in het rood
07/06/22	Overname Acacia afgerond
20/05/22	Bel20 sluit week hoger af
20/05/22	Brussel omhoog

More news

Managers and Directors: Acacia Pharma Group plc

Manager	Title	Age	Since
Gabriel Fox CTO	Chief Tech/Sci/R&D Officer	-	31/12/2007
Debra M. Hussain PRN	Corporate Officer/Principal	-	18/05/2021
Anne-Marie Elsley SEC	Corporate Secretary	-	28/02/2020

Director	Title	Age	Since
Ed Borkowski BRD	Director/Board Member	66	28/02/2018
John Brown BRD	Director/Board Member	71	28/02/2018
Scott Byrd CHM	Chairman	56	01/03/2020

More insiders

Acacia Pharma Group plc specializes in the research and development of supportive care medicines. The products are intended to support the side effects of anti-cancer treatments (including nausea and vomiting drugs). At the end of 2021, the group had a portfolio of 3 products, including 1 in phase II of clinical development (APD403; treatment of chemically induced nausea and vomiting) and 2 in pre-launch phase: BARHEMSYS (treatment of nausea and postoperative vomiting) and BYFAVO (benzodiazepine sedative for use in invasive medical procedures in adults, such as colonoscopy and bronchoscopy).

Employees

Sector

More about the company

Date	Insider	Type	Main position	Quantity	% Market Cap.
23/03/22	Michael Bolinder	Exercice	Chief Executive Officer	63,710	0.0632%
08/01/22	John Brown	Buy	Director	5,001	0.0050%
08/01/22	Ed Borkowski	Buy	Director	5,001	0.0050%